

Press release 2015-08-24

WntResearch announces last patient initiated treatment in the clinical phase 1 study

WntResearch today announces that the last patient has initiated treatment on the last dose level (dose level 8) in their on-going clinical phase 1 study with Foxy-5.

Nils Brünner, CEO says, *"I am very satisfied that we have identified, enrolled and started to treat the last patient in our phase 1 study with Foxy-5. During Q4, as the results of the complete study are analysed, we will present a summary report containing the available data from the study"*.

Nils Brünner continues, *"Meanwhile, we are finalising the study protocol for the phase 1b study, which we aim to initiate as soon as possible. We are also continuing our work planning for the upcoming phase 2 study"*.

For additional information please contact:

Nils Brünner, CEO
E-mail: nbr@wntresearch.com
Telephone: + 45 2614 4708

About WntResearch

WntResearch AB is a public company on the AktieTorget in Sweden. WntResearch develops the anti-cancer compound Foxy-5 to be used to combat the metastatic process of cancer. WntResearch has one drug candidate in clinical phase 1 – Foxy-5 – as well as one candidate drug in preclinical development – Box-5. The Company is currently focusing mainly on the development of Foxy-5.